In This Article:
Villers-lès-Nancy, 7 November 2024 - 6:00 p.m. (CET)
PRESS RELEASE
2024 nine-month revenue: €158.2 million
Return to growth in Q3 (+0.3%)
| Revenue (€m) | 2023 | 2024 | Change / | - Ségur | +Ségur | - External Growth | Change / | ||
| Q1 | 56.2 | 53.3 | -2.9 | -5.2% | 0.3 | 1.4 | 2.0 | -3.8 | -6.7% |
| Q2 | 56.4 | 54.7 | -1.7 | -3.0% | 0.3 | 1.2 | 1.7 | -2.6 | -4.6% |
| Q3 | 50.1 | 50.2 | 0.1 | 0.3% | 0.2 | 0.3 | 1.8 | -1.5 | -3.0% |
| Total | 162.7 | 158.2 | -4.5 | -2.8% | 0.9 | 2.9 | 5.5 | -7.9 | -4.9% |
At September 30, 2024, Equasens Group reported year-to-date revenue of €158.2m, down 2.8% on a reported basis from one year earlier and 4.9% like-for-like.
-
Improved momentum in Q3 both on a reported and like-for-like basis, with renewed growth by all divisions except AXIGATE LINK which has been growing since the beginning of the year.
-
Stable contributions from acquisitions, up 3.5% in the quarter.
Operating highlights:
| Year-to-date revenue at 30 September by business (€m) | 2023 | 2024 | Change / Reported basis | |
| Sale of configurations and hardware | 70.3 | 62.7 | -7.5 | -10.7% |
| Scalable maintenance and professional training services | 58.3 | 60.5 | 2.2 | 3.8% |
| Software solutions and subscriptions | 32.2 | 33.0 | 0.8 | 2.6% |
| Other services (including intermediation) | 1.9 | 1.9 | 0.0 | -0.7% |
| TOTAL | 162.7 | 158.2 | -4.5 | -2.8% |
-
A smaller decline in configuration and hardware sales (-5.0% in Q3 alone, compared with -12.9% in H1) in the Pharmagest and e-Connect Divisions.
-
Scalable maintenance services and business training continue to grow, albeit at a slower pace (+0.5% in Q3 2024), while e-learning sales are down.
-
The software solutions and subscriptions business registered strong growth (+11.4% in Q3 compared with -0.9% in H1), with a significantly smaller Ségur base effect (€0.1m). Acquisitions in 2024 also significantly contributed to the segment's growth.
| Year-to-date revenue at 30/09 / Division (€m) | 2023 | 2024 | Change / | - Ségur | +Ségur | - External Growth | Change / | ||
| Pharmagest | 120.5 | 120.1 | -0.4 | -0.4% | 0.4 | 1.4 | 5.4 | -4.9 | -4.0% |
| Axigate Link | 22.3 | 22.6 | 0.3 | 1.5% | 0.2 | 0.9 |
| 1.0 | 4.7% |
| e-Connect | 11.7 | 8.3 | -3.5 | -29.5% |
|
|
| -3.5 | -29.5% |
| Medical Solutions | 6.7 | 5.8 | -1.0 | -14.2% | 0.2 | 0.6 | 0.1 | -0.7 | -10.0% |
| Fintech | 1.5 | 1.5 | 0.0 | 1.6% |
|
|
| 0.0 | 1.6% |
| Total | 162.7 | 158.2 | -4.5 | -2.8% | 0.9 | 2.9 | 5.5 | -7.9 | -4.9% |
-
The PHARMAGEST Division ended Q3 2024 with revenue of €38.0m, up 3.2% on Q3 2023 and marginally down year-to-date (-0.4% to €120.1m).
-
In France, with revenue up 0.9% over the quarter and 2.7% year-to-date respectively, business was notably driven by software solutions and subscriptions (+62.6% in Q3), with acquisitions in 2024 contributing €1.0m in the quarter.
-
Configuration and hardware sales remain down (-1.6% in Q3) with the electronic label market remaining sluggish (-€0.7m).
-
In the rest of Europe, growth remained strong, gaining 24.0% in the quarter and 19.8% year-to-date. Italy contributed significantly to this good performance (+7.5% in Q3) while PHARMAGEST Germany added €0.7m to revenue for the quarter and €2.2m year-to-date.
-